Participation in the European Framework Program Projects
• METAFIGH
The project is composed of 10 partners led by the Italian University of Torino to develop an approach to the problem of metastasis in primary cancer through a series of studies to understand the cellular mechanisms that occur.
• NANOTHER
The project is composed of 18 partners led by the Gaiker Foundation (Basque Country) and seeks to define and integrate technology-based nanoparticles for the diagnosis of several types of cancer as well as research in design "nano" to create systems for controlled the drug delivery.
• MAMBA
Marine Metagenomics Biotechnological Applications for new (Collaborative Project). The project is composed of 13 partners led by the Wales University of Bangor (United Kingdom) and is focused on the discovery and use of new microbial activities, ie, "mining" of enzymes and metabolic pathways of marine organisms and extremophiles metagenomics microbial community using enzymatic reactions and processes for new biotechnological applications, in particular for the production of fine chemicals, antioxidant and antitumor drugs.
• Network of connective tissue cancers (Conticanet)
It is a network of excellence that includes researchers from 20 academic centers and companies to promote and unite efforts in the investigation of rare types of cancer or cancer of the low prevalence in adults and children. Led by the Claude Bernard University in Lyon (France), the network integrates multidisciplinary research groups, ranging from basic research to translational and clinical research, as well as several pharmaceutical companies. The aim is to integrate a critical mass of resources and knowledge to not only understand the etiology of disease, but to seek diagnosis and open the door to new therapeutic options.
• CAPPELLA
This project is composed of 9 members headed by the switzerland company Evolve SA and aims to develop a series of tools and libraries of small ligands that enable new approaches to the inhibition of protein-protein interactions in cancer, one of the most promising approaches for developing new therapies against cancer.
CENIT Program
• NANOFARMA Consortium (CENIT 2006-2009)
Nanofarma is a consortium led by PhamaMar, composed by seven spanish companies, whose goal is research and joint development of nano systems with applications in the pharmaceutical sector. The consortium implementing the project CENIT: “Systems Targeted Drug Delivery”, sponsored by the Industrial Technology Development Center (CDTI) within the CENIT program. The project aims at the development of DDS (Drug Delivery Systems), suitable for oral or parental administration, capable of selectively led to the drug to the organ, tissue or target cell, which would give the Spanish pharmaceutical industry engines to acquire highly competitive pharmaceutical industry requires, as the engines of innovation in drug delivery systems, which seeks more effective and safe and reduced health care costs.
The companies of the consortium, plus PharmaMar are: Rovio Laboratories, Faes Farma, Sylentis, Noscira, Déndrico and Lipotec.
The consortium also is in the form of outsourcing to more than twenty public schools whose spanish researchers in different drug delivery systems. Among these centers include: the University of Santiago de Compostela, Universidad de Navarra, University of Seville, Universidad de Valladolid, Universidad Complutense de Madrid, several research centers belonging to the Centro Superior de Investigaciones Científicas, Fundació Clínic per The Biomedical Research, University Miguel Hernández, the Barcelona Science Park, the Autonomous University of Madrid, the University of Basque Country, etc…
• Melius Consortium (CENIT 2007-2010)
PhamaMar is part of the Melius consortium, which conducts the R & D project entitled "Improving the prediction of translational non-clinical safety testing to man", who leads Noscira (also Zeltia Group company), submitted and approved in the CENIT Program second call managed by CDTI.
The project aims at studying the application of new technologies (proteomics, genomics, cytomics, metabolomics) to improve the translational results prediction of early research and non-clinical research to the man. Indeed, improving the translational results prediction in the process of drug research and development has been considered by the European Platform on Innovative Medicines as a key to get safer and more effective drugs.
The project aims at studying the application of new technologies (proteomics, genomics, Cytomics, metabolomics) to improve the prediction results of translational research in non-clinical and early man. Indeed, improving the prediction in the process of translational research and drug development has been considered by the European Platform on Innovative Medicines as a key to solving for drugs safer and more effective.
Alongside Noscira and PharmaMar, in the consortium there are four SMEs specializing in differents biotechnology fields (Progenika Biopharma SA, Proteomika SL, OWL Genomics SL, NewBiotechnic SA) and two other pharmaceutical companies (Rovio SA and Faes Farma SA) specializing in various therapeutic areas such as oncology, diseases of the central nervous system, bone diseases and cardiovascular diseases.
Also, this project involves a number of public schools under the subcontracting. Among them are University Hospital “La Fe de Valencia”, Barcelona Science Park, Felipe Prince Research Center, Molecular Biology Center of CSIC, Barcelona Autonomous University, Biomedical Research Institute, IMIM Foundation, etc…